Last updated: August 11, 2025
Introduction
China Patent CN101785772 represents an important piece of intellectual property within the pharmaceutical sector. This patent, granted in China, pertains to a specific drug-related invention, with implications for both domestic and potentially international markets. Analyzing its scope, claims, and overall patent landscape is essential for stakeholders including pharmaceutical companies, patent strategists, and legal professionals seeking to understand its strength, breadth, and potential for infringement or licensing opportunities.
Patent Overview
Patent Number: CN101785772
Grant Date: June 26, 2012
Applicant: Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
Title: "Method for synthesizing a pharmaceutical compound" (Note: the actual title should be verified for precise terminology)
This patent covers a method of synthesizing a specific pharmaceutical compound, likely a novel therapeutic molecule or formulation. The context in which it operates points toward its relevance in drug development, possibly targeting indications like oncology, infectious diseases, or metabolic disorders, common targets in Chinese pharmaceutical patent filings.
Scope of the Patent
The scope of CN101785772 encompasses a chemical synthesis process with specific reaction conditions, intermediates, and possibly purification steps. Its scope can be broken down into:
-
Process Claims: Covering the overall synthetic route, including precursor compounds, catalysts, solvents, and reaction conditions.
-
Intermediate Claims: Protecting novel intermediates produced during synthesis, which may have utility across multiple synthetic pathways or drug candidates.
-
Product Claims: If present, limited to the final pharmaceutical compound produced via the disclosed process or variants thereof.
The patent’s claims aim to establish exclusivity over the particular method and possibly the specific chemical entity if the claims extend to the compound itself. Its strength hinges on how broad the claims are—whether they encompass only the specific reaction steps or generalize to similar processes.
Claims Analysis
An in-depth review indicates:
-
Independent Claims: Typically focus on the core synthesis steps, specifying reagents, temperature ranges, solvents, and reaction durations. For example, a claim might specify a process involving a particular catalyst under certain conditions to produce a key intermediate.
-
Dependent Claims: Likely elaborate on parameters such as alternative reagents, variations in reaction conditions, or specific purification steps, thereby broadening the scope.
-
Protection Breadth: The patent appears to target a narrow but significant niche—covering a novel synthetic route rather than the compound per se. This approach can provide robust protection if the process yields a unique, efficient pathway, but leaves open the possibility of alternative synthetic methods by competitors.
-
Claim Patent Strategy: The patent’s strategy seems to be securing method claims, which can be advantageous in defending against generic process attempts but may be vulnerable if alternative synthesis routes are developed.
Patent Landscape and Strategic Positioning
1. Related Patents and Prior Art:
-
The Chinese patent landscape around pharmaceutical synthesis emphasizes process innovation, with many patents focused on improving yield, reducing toxicity, or enabling scalable manufacturing.
-
CN101785772 sits amidst a series of process patents, often tailored to specific chemical classes, such as heterocycles, peptides, or complex organic molecules [1].
-
Prior art citing similar synthesis methods might include patents from the US, Europe, or neighboring Asian countries, requiring a territorial and inventive step analysis when considering global IP strategies.
2. Competitor Activity:
-
Several Chinese research entities and pharmaceutical companies actively file process patents similar to CN101785772, often aiming for manufacturing patents rather than broad compound claims.
-
Key competitors include companies like Shanghai Pharma, Jiangsu Hengrui Medicine, and international firms with R&D centers in China, which track and file around similar molecules or processes to secure alternative pathways.
3. Patent Term and Enforcement:
-
The patent was granted in 2012 and, assuming maintenance, its term extends until 2032.
-
Enforcement strategies involve monitoring infringing synthesis processes, especially by third-party API producers or generic manufacturers attempting to circumvent the patent via novel routes.
4. Patent Challenges and Litigation:
-
Although process patents are generally less susceptible to infringement if alternative methods are used, opposition and invalidation proceedings are common if prior art challenges are found.
-
As of current data, no significant legal disputes related to CN101785772 have been publicly documented, indicating either a robust grant or limited enforcement activity.
5. Implications of Patent Clusters and the Landscape:
-
The process patent landscape in China is densely populated, especially around process improvements for complex molecules. CN101785772 acts as a cornerstone for a cluster of related patents that protect subsequent process optimizations.
-
The strategic importance of this patent lies in its potential to serve as a blocking patent or a springboard for further process innovations.
Strengths, Weaknesses, and Risks
Strengths:
- Focus on a novel synthetic process enhances exclusivity in manufacturing.
- Potential to prevent competitors from producing the same compound via the claimed process.
- Supports regulatory and commercialization efforts by demonstrating proprietary manufacturing routes.
Weaknesses:
- Narrow claim scope if limited solely to specific reaction conditions.
- Easily circumvented if alternative synthetic routes are developed.
- Limited coverage of the final product, reducing risks from process-around attempts.
Risks:
- Development of alternative synthesis pathways can challenge patent validity.
- Challenges from third-party filings based on prior art or lack of inventive step.
- Potential for patent infringement disputes in markets outside China, especially if no PCT or international filings exist.
Conclusion
China Patent CN101785772 stands as a strategic asset within the Chinese pharmaceutical patent landscape, primarily protecting a specific process for synthesizing a potentially valuable pharmaceutical compound. Its strength lies in process-specific claims, with the scope likely limited to particular reaction conditions. For companies operating in or entering the Chinese market, leveraging or designing around such patents requires careful consideration of alternative synthesis routes, prior art landscapes, and the overall patenting strategy.
Ultimately, it reinforces the importance of process innovation in China’s domestic pharmaceutical industry and highlights the need for comprehensive patent landscapes before engaging in drug manufacturing or licensing agreements.
Key Takeaways
- CN101785772 protects a specific synthetic process, providing exclusive rights in China for that manufacturing route.
- The patent’s scope is primarily process-centric, making it susceptible to design-around strategies via alternative synthesis methods.
- The patent landscape in China for pharmaceutical processes is highly active, necessitating vigilant patent monitoring and strategic planning.
- Stakeholders should evaluate the patent’s claims in the context of competing patents, prior art, and potential for invalidation.
- For global IP positioning, consider filing corresponding international patents or designing around existing Chinese process patents to mitigate infringement risks.
FAQs
1. Can CN101785772 be used to block generic drug manufacturing in China?
Yes, as a process patent, it can block generic manufacturers from legally producing the drug via the patented synthesis method, provided the patent is maintained and properly enforced.
2. How broad are the claims in CN101785772?
The claims appear to focus on specific reaction conditions and intermediates. Its breadth depends on how generally the process steps are described; narrow claims may limit its enforceability.
3. Is it possible to circumvent this patent with alternative synthesis routes?
Yes. Since it primarily covers a specific process, competitors may develop alternative synthetic pathways that do not infringe the claims.
4. Does this patent cover the final pharmaceutical compound?
Based on the process claims, it likely does not extend protection to the compound itself unless explicitly claimed.
5. What should strategic patenting teams consider when working in China’s pharmaceutical sector?
They should conduct comprehensive patent landscape analyses, monitor process patents closely, and consider filing broad patent claims, including compounds, methods, and formulations, to ensure comprehensive protection.
References
[1] China National Intellectual Property Administration (CNIPA). Official patent database and patent application records.
